Anna Szeremeta

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Rheumatoid Arthritis

Interstitial Lung Disease

Prognostic Factors

Top Venues

Journal of clinical medicine

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Anna Szeremeta, Agnieszka Jura-Półtorak, Aleksandra Zoń-Giebel, Krystyna Olczyk, Katarzyna Komosinska-Vassev
Plasma Sclerostin Levels in Rheumatoid Arthritis Women on TNF-α Inhibitor Therapy. Pharmaceuticals (Basel, Switzerland) 17 (6) (2024)
Anna Szeremeta, Agnieszka Jura-Półtorak, Aleksandra Zoń-Giebel, Krystyna Olczyk, Katarzyna Komosinska-Vassev
Plasma Sclerostin Levels in Rheumatoid Arthritis Women on TNF-α Inhibitor Therapy. Pharmaceuticals (Basel, Switzerland) 17 (6) (2024)
Anna Szeremeta, Agnieszka Jura-Półtorak, Aleksandra Zoń-Giebel, Krystyna Olczyk, Katarzyna Komosinska-Vassev
Effects of Etanercept and Adalimumab on Serum Levels of Cartilage Remodeling Markers in Women with Rheumatoid Arthritis. Journal of clinical medicine 12 (16) (2023)
Anna Szeremeta, Agnieszka Jura-Półtorak, Aleksandra Zoń-Giebel, Krystyna Olczyk, Katarzyna Komosinska-Vassev
TNF-α Inhibitors in Combination with MTX Reduce Circulating Levels of Heparan Sulfate/Heparin and Endothelial Dysfunction Biomarkers (sVCAM-1, MCP-1, MMP-9 and ADMA) in Women with Rheumatoid Arthritis. Journal of clinical medicine 11 (14) (2022)
Agnieszka Jura-Półtorak, Anna Szeremeta, Krystyna Olczyk, Aleksandra Zoń-Giebel, Katarzyna Komosinska-Vassev
Bone Metabolism and RANKL/OPG Ratio in Rheumatoid Arthritis Women Treated with TNF-α Inhibitors. Journal of clinical medicine 10 (13) (2021)